JN-210

About Jaan Biotherapeutics

Jaan Biotherapeutics is pioneering a regenerative medicine approach for cardiovascular diseases by targeting a conserved microRNA program to stimulate heart muscle repair. The company's lead programs focus on reducing infarct size in ischemic heart disease (IHD) and treating hypertrophic cardiomyopathy (HCM), with plans to initiate clinical trials in 2027. It has secured significant intellectual property with over 30 patents and has been supported by multiple NIH Small Business grants. Jaan is currently seeking funding to advance its programs toward IND filings.

Therapeutic Areas

Other Hypertrophic Cardiomyopathy (HCM) Drugs